Inflammatory response to the anti PD-L1 drug, atezolizumab, masquerades as breast implant rupture

  • Marie-Eve MarcotteEmail author
  • François Panet
  • Etienne Croteau
  • Marie-Anne Richard
  • Michel Pavic
  • Marc-André Levasseur
Image of the Month
Part of the following topical collections:
  1. Image of the month


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Consent from the patient

Written informed consent was obtained from the patient.


  1. 1.
    Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559–74.CrossRefPubMedGoogle Scholar
  3. 3.
    Mitchell MA, Hogan K, Amjadi K. Atezolizumab-induced sarcoid-like granulomatous reaction in a patient with urothelial cell carcinoma. Immunotherapy. 2018;10:1189–92.CrossRefPubMedGoogle Scholar
  4. 4.
    Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-induced sarcoidosis-like reactions. Chest. 2018;154:664–77.CrossRefPubMedGoogle Scholar
  5. 5.
    Hillard C, Fowler JD, Barta R, Cunningham B. Silicone breast implant rupture: a review. Gland Surg. 2017;6:163–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Nuclear Medicine and Radiobiology, Faculty of Medicine and Health SciencesSherbrooke UniversitySherbrookeCanada
  2. 2.Department of Hematology–Oncology, Faculty of Medicine and Health SciencesSherbrooke UniversitySherbrookeCanada
  3. 3.Sherbrooke Molecular Imaging Center (CIMS), Sherbrooke University Hospital Research Center (CR-CHUS)SherbrookeCanada

Personalised recommendations